Sv: DDB128

[Sonia Nielsen <sonianie@xxxxxxxxxxxxx>]

----------
> Fra: John Cottingham <jcott@xxxxxxxxx>
> Til: Multiple recipients of list PARKINSN <PARKINSN@xxxxxxxxxxxxxxxxxxxx>
> Emne: Re: DDB128
> Dato: 3. maj 1997 05:27
>
> At 09:55 PM 5/2/97 -0400, you wrote:
> >Bestwishes from Philip Dunn]
> >pdunn@xxxxxxxxxxx
> >
> >
> tolcapone / Tasmar (R)
> ANTIPARKINSON: Dopamine agonist: TRIAL PHASE
>
> Tolcapone is the most potent COMT inhibitor currently
> in clinical development. Studies in patients with Parkinson's
> disease in the United States and Europe are complete.
snip
  Tolcapone > should be an important development in the treatment of
> Parkinson's disease.
> snip
>
>
> jcott@xxxxxxxxx    That man may last, but never lives,
>                     Who much receives, but nothing gives;
> HomeBoy #Parkinsons  Whom none can love, whom none can thank,
>                       Creation's blot, creation's blank.
> John Cottingham        Thomas Gibbons (1720-1785):
>                         When Jesus dwelt.
>
>
> Hello John, BUT WHEN?
Here in Denmark we have been told SOON, but what is soon? is it month or a
year?
Do you know something about that?

Best regards
Sonia

NEVER GIVE UP
>
>
>
>
>
>
>
>